Beyond One Gene: a systematic review of layered evidence for antileishmanial resistance in Leishmania infantum.

Infect Genet EvolAug 20, 2026 (epub)
Clinical ResearchMedical GeneticsInfectious Diseases

Ricardo Vieira Costa, Marcelo Cerilo-Filho, Maria Naely Gomes Almeida et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined genetic evidence for antileishmanial resistance in Leishmania infantum, focusing on 29 studies. It identified key genetic loci associated with altered drug susceptibility, particularly for miltefosine and antimonials. The findings suggest that resistance is influenced by multiple genetic factors rather than a single marker.

Key findings

  • Evidence concentrated on antimonials, miltefosine, amphotericin B, and allopurinol.
  • MT/ROS3 miltefosine transport axis and MRPA-associated antimony resistance were consistently supported.
  • MSL deletion linked to miltefosine treatment failure or relapse.
  • Expression studies showed heterogeneous profiles for antimony-related uptake.

Why it matters

Understanding the genetic basis of drug resistance in Leishmania infantum is crucial for developing effective treatment strategies and improving patient outcomes in visceral leishmaniasis management.

Source

PubMed · PMID 42624345

Published in Infect Genet Evol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Medical Genetics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.